ARTICLE | Clinical News

Autologous T cell therapy against CD19: Phase Ib/II started

October 10, 2016 7:00 AM UTC

Kite began the open-label, U.S. Phase Ib/II ZUMA-6 trial to evaluate IV KTE-C19 plus Tecentriq atezolizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) in about 31 patients. After receiving a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, patients will receive KTE-C19 followed by Tecentriq, a human mAb against PD-L1. ...